Total Human Serum Free IgE Immunoenzymetric Assay (IEMA)

Xolair (generic name, omalizumab) is currently approved by the FDA for the treatment of extrinsic asthma. Presently, there are no serological markers or assays for monitoring the efficacy of prolonged Xolair therapy in patients with extrinsic asthma. Monitoring the free IgE level in the blood is one indicator of Xolair efficacy since the drug's action is expected to decrease the "free" IgE by greater than 95%. Scientists at JHU have now developed a novel assay to determine the efficacy of Xolair by using anti-IgE to capture IgE and a biotinylated alpha chain to detect free IgE. The invention is the first known assay to detect free human IgE (unbound with Xolair) in human serum. Description (Set) Proposed Use (Set) The commercial potential for a total serum free human IgE immunoenzymetric assay is promising since every patient who receives Xolair (Omalizumab) is a potential candidate for a free IgE measurement. In addition, this assay may be developed as a predictive tool as free IgE levels might allow one to calculate the success of Xolair treatment in asthma patients.

Inventor(s): Hamilton, Robert G.

Type of Offer: Licensing

Next Patent »
« More Medical Patents

Share on      

CrowdSell Your Patent